Journal
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
Volume 8, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fcimb.2018.00114
Keywords
Mycobacterium tuberculosis; drug resistance; molecular; comorbidities; therapeutic; drug targets
Categories
Funding
- National Natural Science Foundation of China [81572037]
- Chinese Academy of Sciences [154144KYSB20150045, KFZD-SW-207]
- National Mega-project of China for Innovative Drugs [2018ZX09721001-003-003]
- National Mega-project of China for Main Infectious Diseases [2017ZX10302301-003-002]
- State Key Lab of Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University [SKLRD2016ZJ003, 2014SKLRD-O06]
- UCAS Ph.D. Fellowship Program
- CAS-TWAS President's Ph.D. Fellowship Program
- Guangzhou Municipal Industry and Research Collaborative Innovation Program [201508020248, 201604020019]
- Guangzhou Municipal Clinical Medical Center Program [155700012]
- National Research Foundation in Korea (NRF) - Ministry of Science, ICT and future Planning (MSIP) [NRF-2017M3A9G6068246, 2015R1C1A1A01053355]
- French ministry of Foreign Affairs
- Valery N. Danilenko, Vavilov Institute of General Genetics, Russian Academy of Sciences
- National Research Foundation of Korea [2015R1C1A1A01053355] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
Tuberculosis (TB) is a formidable infectious disease that remains a major cause of death worldwide today. Escalating application of genomic techniques has expedited the identification of increasing number of mutations associated with drug resistance in Mycobacterium tuberculosis. Unfortunately the prevalence of bacillary resistance becomes alarming in many parts of the world, with the daunting scenarios of multidrug-resistant tuberculosis (MDR-TB), extensively drug-resistant tuberculosis (XDR-TB) and total drug-resistant tuberculosis (TDR-TB), due to number of resistance pathways, alongside some apparently obscure ones. Recent advances in the understanding of the molecular/genetic basis of drug targets and drug resistance mechanisms have been steadily made. Intriguing findings through whole genome sequencing and other molecular approaches facilitate the further understanding of biology and pathology of M. tuberculosis for the development of new therapeutics to meet the immense challenge of global health.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available